Chr t(11;14)

P2, N=490, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2029

Serum soluble B cell maturation antigen levels did not differ between patients with or without detectable CTPCs in MGUS or SMM. These findings highlight the distinct phenotypic and cytogenetic characteristics of CTPCs in MGUS and SMM, and provide insights regarding their biological features and pathogenesis.

P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026

The recent therapy of PCL is similar to that of other high-grade myelomas, taking advantage of anti-proteasome, like bortezomib, an immunomodulator, like lenalidomide, and dexamethasone triplet + anti-CD38 antibody and/or cyclophosphamide, and hematopoietic stem cell transplantation. However, the results are not as good as in the other forms of myeloma.

P3, N=529, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Oct 2026

P1, N=24, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

P2, N=151, Completed, Alliance for Clinical Trials in Oncology | Active, not recruiting --> Completed

P2, N=39, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Jun 2025 --> Mar 2026

P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025

Despite these differences, progression-free survival with frontline treatment (HR: 0.97, 95% CI: 0.84-1.11, p = 0.63) and overall survival (HR: 0.99, 95% CI: 0.87-1.13, p = 0.94) were similar between LCMM and non-LCMM patients. This study highlights the distinct clinical and cytogenetic features of LCMM, marked by higher rates of renal failure, t(11;14), and del(13q), lower prevalence of IMS-IMWG high-risk disease, and comparable survival outcomes.

in real world, more than one third of MM patients do not have baseline FISH data. Nevertheless, cytogenetics and ECOG PS can be used for prognostic staging and for tailoring therapy.

ATM deletion is an important predictor of prognosis in MCL patients and should be routinely examined, especially in those with wild-type TP53. In contrast, an isolated ATM mutation may predict a better prognosis in the context of standard immunochemotherapy.